NLRP3 inflammasome is a target for development of broad-spectrum anti-infective drugs.

Authors:
Address: Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. jim_thacker@therimunex.com
Journal:

Publication:

abstract

We describe the molecular mode of action and pharmacodynamics of a new molecular entity (NME) that induces the NLRP3 inflammasome-mediated innate immune response. This innate response reduces the pathogen load in an experimentally induced methicillin-resistant Staphylococcos aureus infection, enhances survival in an experimentally induced Gram-negative bacteremia, and overrides the escape mechanism of an obligate intracellular pathogen, viz. Chlamydia pneumoniae. Furthermore, the NME is more effective than standard-of-care antibiotic therapy in a clinically established multifactorial bacterial infection. Analysis of transcriptional regulation of inflammasome signaling genes and innate/adaptive immune genes revealed consistent and significant host changes responsible for the improved outcomes in these infections. These studies pave the way for the development of first-in-class drugs that enhance inflammasome-mediated pathogen clearance and identify the NLRP3 inflammasome as a drug target to address the global problem of emerging new infectious diseases and the reemergence of old diseases in an antibiotic-resistant form.

Related Articles
Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR/nucleotide-binding oligomerization domain-mediated NF-kappa B signaling.
J Immunol. 2010
Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR/nucleotide-binding oligomerization domain-mediated NF-kappa B signaling.
Toma C, Higa N, Koizumi Y, Nakasone N, Ogura Y, McCoy AJ, Franchi L, Uematsu S, Sagara J, Taniguchi S, et al. J Immunol. 2010 May 1; 184(9):5287-97. Epub 2010 Mar 26.
[The history of the development and changes of quinolone antibacterial agents].
Yakushigaku Zasshi. 2003
[The history of the development and changes of quinolone antibacterial agents].
Takahashi H, Hayakawa I, Akimoto T. Yakushigaku Zasshi. 2003; 38(2):161-79.
Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells.
PLoS One. 2009
Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells.
Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA. PLoS One. 2009 Oct 14; 4(10):e7446. Epub 2009 Oct 14.
Review Molecular mechanism of NLRP3 inflammasome activation.
J Clin Immunol. 2010
Review Molecular mechanism of NLRP3 inflammasome activation.
Jin C, Flavell RA. J Clin Immunol. 2010 Sep; 30(5):628-31. Epub 2010 Jun 30.
Review Innate instruction of adaptive immunity revisited: the inflammasome.
EMBO Mol Med. 2009
Review Innate instruction of adaptive immunity revisited: the inflammasome.
Eisenbarth SC, Flavell RA. EMBO Mol Med. 2009 May; 1(2):92-8.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.